This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Using an inhaled glucocorticoid in addition to usual care reduced the rate of severe asthma exacerbations and improved other markers of disease severity. Adding an inhaled glucocorticoid to usual care ...

The study uncovers high reliance on oral corticosteroids for asthma in Italy, pointing to gaps in guideline adherence and the ...

Inhaled and oral glucocorticoids are associated with structural changes in the brain that may help explain some of the neurological and psychological side effects seen with these drugs, a new study ...

CNN — Taking oral or inhaled glucocorticoids, a type of steroid used to curb inflammation in asthma and other autoimmune disorders, may be linked to damaging changes in the white matter of the brain, ...

People who take oral or inhaled glucocorticoids – steroids commonly used to curb inflammation in asthma and allergies – may experience changes in the white matter of the brain, leading to cognitive ...

In patients with asthma, current glucocorticoid use was associated with a higher risk of idiopathic venous thromboembolism (VTE), particularly in those with systemic use and those who received ...

Although asthma burden is greater and more debilitating in blacks, historically, blacks have been underrepresented in asthma trials, which have primarily been conducted in white populations with ...

Dupilumab (interleukin-4Rα; antibody binds to interleukin-4Rα, inhibiting interleukin-4 and interleukin-13 signaling in hematopoietic cells [e.g., B cells, CD4+ helper T cells, and eosinophils], ...

PHOENIX -- Black and Latinx patients who used an inhaled glucocorticoid as needed along with usual care had improved asthma outcomes, according to results from the PREPARE trial. Patients in the ...

Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. A study published this week in the journal BMJ Open finds a possible ...

Adding a novel, ultra-long-acting biologic to standard care for patients with severe asthma and type 2 inflammation significantly reduced exacerbations, a pair of phase IIIA trials showed. Across the ...